Pancreatic organoids as cancer avatars for true personalized medicine

Area of Science:

• Oncology
• Translational Research
• Cancer Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with poor survival rates and limited therapeutic options.
• High genetic heterogeneity in PDAC challenges the development of effective treatments and personalized medicine approaches.
• Existing preclinical models often fail to capture the complexity of PDAC, hindering translational research.

Purpose of the Study:

• To review the revolutionary potential of patient-derived organoids (PDOs) in advancing precision oncology for pancreatic cancer.
• To discuss how PDOs can improve clinical decision-making by predicting tumor response to therapies.
• To explore the utility of PDOs as preclinical platforms for biomarker and drug discovery in PDAC.

Main Methods:

• Utilizing patient-derived organoids (PDOs) as in vitro models that preserve the genetic, transcriptomic, proteomic, and epigenetic characteristics of parental tumors.
• Reviewing current literature on the application of PDOs in pancreatic cancer research and clinical translation.
• Analyzing the potential of PDOs for prognosticating treatment response and facilitating drug discovery.

Main Results:

• PDOs faithfully recapitulate the inter- and intratumoral heterogeneity of pancreatic ductal adenocarcinoma.
• PDO models demonstrate significant promise in predicting patient response to various therapeutic interventions.
• Organoid-based systems are emerging as valuable tools for identifying novel biomarkers and therapeutic targets.

Conclusions:

• Patient-derived organoids are poised to revolutionize precision oncology in pancreatic cancer by enabling personalized treatment strategies.
• PDOs can significantly assist in clinical decision-making through accurate prognostication of tumor response.
• Further development of organoid-based systems will enhance their predictive power for therapy response and accelerate drug discovery.